Risperidone-induced acromegaly: a case report
- PMID: 23983960
- PMCID: PMC3736930
- DOI: 10.1177/2045125311433581
Risperidone-induced acromegaly: a case report
Abstract
Today, considering their adverse side effects, the first-generation antipsychotics have been replaced by the new-generation antipsychotics (also known as second-generation antipsychotic agents). The superiority of new-generation antipsychotics compared with first-generation antipsychotic agents in terms of side effects, especially movement disorders, are acknowledged by clinicians. But in recent years during the use of second-generation antipsychotic agents, endocrine side effects have been noteworthy. In our study with a diagnosis of paranoid schizophrenia treated with risperidone for 14 years and operated with the diagnosis of pituitary macroadenoma, a 32-year-old female patient is presented in the light of the literature examining the framework of the history of disease.
Keywords: acromegaly; endocrine side effects; risperidone.
Conflict of interest statement
The authors declare no conflicts of interest in preparing this article.
References
-
- Blanc O., Brousse G., Meary A. (2010) Pharmacogenetic of response efficacy to antipsychotics in schizophrenia: pharmacodynamic aspects. Review and implications for clinical research. Fundamental Clin Pharmacol 24: 139–160 - PubMed
-
- Coccurello R., Moles A. (2010) Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther 127: 210–251 - PubMed
-
- Debono M., Newell-Price J. (2010) New formulations and approaches in the medical treatment of acromegaly. Curr Opin Endocrinol Diabetes Obes 17: 350–355 - PubMed
-
- Erer S., Yilmazlar S., Zarifoglu M., Guclu M. (2008) A case report on pituitary macroadenoma presented as hemichorea hemiballism syndrome. Dialogues Clin Neurosci 29: 289–290 - PubMed
LinkOut - more resources
Full Text Sources